Company signals · Biotech & Pharma
Neurocrine Biosciences
2 signals in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: MitchelLake's Talent Market Index sits at 105.8 (Hot), down 2.3 on the prior month; Americas hiring signal is running rising (+2.4pts).
Neurocrine Biosciences: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 24 tracked companies; 0.1% of MitchelLake's Americas signal flow; 2 tracked across 21 days.
Signals at Neurocrine Biosciences
Product Launch
AmericasNeurocrine initiated Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. infants and toddlers (3 months to under 4 years) with classic congenital adrenal hyperplasia, with concurrent EU trial at target enrollment. Moving toward supplemental U.S. filing to extend indication into pediatric population with no approved therapies.
Leadership read: Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.
curated · 2026-07-10 · context →
Product Launch
AmericasNeurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Leadership read: Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.
curated · 2026-06-19 · context →
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
Boehringer Ingelheim →Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.
Product Launch · Americas
Bristol Myers Squibb →Bristol Myers Squibb announced FDA acceptance of its New Drug Application for mezigdomide, an oral CELMoD candidate for relapsed or refractory multiple myeloma combination therapy.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Product Launch · Americas
BridgeBio →BridgeBio submitted NDA to FDA for BBP-418 for LGMD2I/R9 treatment, based on positive Phase 3 FORTIFY trial results showing statistically significant improvements
Intelligence powered by Autonodal ↗